Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study

Overview

Journal PLoS Curr

Specialty General Medicine

Date 2011 Dec 6

PMID 22139861

Citations 4

Authors

Ray Dorsey

Kevin Biglan

Shirley Eberly

Peggy Auinger

Alicia Brocht

Chizoba C Umeh

David Oakes

Kathleen Clarence-Smith

Frederick Marshall

Ira Shoulson

Samuel Frank

Affiliations

Soon will be listed here.

Abstract

The safety and effectiveness of tetrabenazine in different sub-populations of Huntington disease (HD) is not known. In this study, we evaluated the safety of tetrabenazine in individuals on an antidepressant and its effectiveness in advanced HD. Tetrabenazine was not associated with an increased incidence of depressed mood among those taking antidepressants and was effective at reducing chorea in those with advanced HD.

Citing Articles

Clinical experience and treatment considerations with vesicular monoamine transport 2 inhibitors.

Johnson K Ment Health Clin. 2024; 14(6):304-312.

PMID: 39703683 PMC: 11616966. DOI: 10.9740/mhc.2024.12.304.

Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians.

Sherman C, Iyer R, Abler V, Antonelli A, Carlozzi N Neuropsychol Rehabil. 2019; 30(6):1150-1168.

PMID: 30849283 PMC: 7685000. DOI: 10.1080/09602011.2018.1564675.

VMAT2 Inhibitors in Neuropsychiatric Disorders.

Tarakad A, Jimenez-Shahed J CNS Drugs. 2018; 32(12):1131-1144.

PMID: 30306450 DOI: 10.1007/s40263-018-0580-y.

Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases.

Shen V, Clarence-Smith K, Hunter C, Jankovic J Tremor Other Hyperkinet Mov (N Y). 2013; 3.

PMID: 24255799 PMC: 3822048. DOI: 10.7916/D8BK1B2D.

References

Jankovic J, Beach J . Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997; 48(2):358-62. DOI: 10.1212/wnl.48.2.358. View

Jeppesen U, Gram L, Vistisen K, Loft S, Poulsen H, Brosen K . Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996; 51(1):73-8. DOI: 10.1007/s002280050163. View

Hayden M, Leavitt B, Yasothan U, Kirkpatrick P . Tetrabenazine. Nat Rev Drug Discov. 2009; 8(1):17-8. DOI: 10.1038/nrd2784. View

Pearson S, Reynolds G . Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology. 1988; 27(7):717-9. DOI: 10.1016/0028-3908(88)90080-9. View

Pettibone D, TOTARO J, Pflueger A . Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol. 1984; 102(3-4):425-30. DOI: 10.1016/0014-2999(84)90562-4. View